1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Hematologic Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J; Xu, J; Zhong, JB | 1 |
| Fujiwara, S; Kawamura, M; Kitayoshi, T; Nishikawa, K; Takatani, M; Terashita, Z | 1 |
| Denizot, Y; Dulery, C; Dupuis, F; Laskar, M; Praloran, V; Rougier, F; Trimoreau, F | 1 |
1 trial(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Hematologic Diseases
| Article | Year |
|---|---|
[Effect of Radix notoginseng saponins on platelet activating molecule expression and aggregation in patients with blood hyperviscosity syndrome].
Topics: Aged; Blood Viscosity; Female; Hematologic Diseases; Hemorheology; Humans; Male; Middle Aged; Panax; Platelet Activating Factor; Platelet Activation; Platelet Aggregation; Saponins; Syndrome | 2004 |
2 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Hematologic Diseases
| Article | Year |
|---|---|
Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs.
Topics: Animals; Blood Circulation; Blood Pressure; Disease Models, Animal; Dogs; Heart; Hematologic Diseases; Hemodynamics; Isoquinolines; Male; Platelet Activating Factor; Platelet Count; Pyridinium Compounds; Shock, Septic; Tetrahydroisoquinolines; Time Factors | 1994 |
Presence and metabolism of lyso platelet-activating factor in human bone marrow.
Topics: Aged; Aged, 80 and over; Bone Marrow; Bone Marrow Cells; Female; Hematologic Diseases; Humans; Inflammation Mediators; Male; Middle Aged; Platelet Activating Factor | 1997 |